Switch theme
Sign up to access all valuation multiples
St Pharm Co Ltd offers custom manufacturing services of Active pharmaceutical ingredients and their intermediates for their use in pharmaceutical development and be compliant to cGMP, requirements. The firm’s business areas include commercial manufacturing of new drug development, manufacturing of generic active pharmaceutical ingredients, fine chemical’s business and development of oligonucleotide therapeutics. The company’s products comprise small molecule active pharmaceutical ingredients, Anti-cancer, Anti- coagulant active pharmaceutical ingredients, etc.
2008
n/a
LTM Revenue $197M
LTM EBITDA $41.4M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ST Pharm has a last 12-month revenue of $197M and a last 12-month EBITDA of $41.4M.
In the most recent fiscal year, ST Pharm achieved revenue of $187M and an EBITDA of $51.8M.
ST Pharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ST Pharm valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $194M | $187M | XXX | XXX | XXX |
| Gross Profit | $60.6M | $76.4M | XXX | XXX | XXX |
| Gross Margin | 31% | 41% | XXX | XXX | XXX |
| EBITDA | $35.8M | $51.8M | XXX | XXX | XXX |
| EBITDA Margin | 18% | 28% | XXX | XXX | XXX |
| Net Profit | $12.3M | $13.3M | XXX | XXX | XXX |
| Net Margin | 6% | 7% | XXX | XXX | XXX |
| Net Debt | $55.0M | $94.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, ST Pharm's stock price is KRW 77500 (or $53).
ST Pharm has current market cap of KRW 1.56T (or $1.1B), and EV of KRW 1.56T (or $1.1B).
See ST Pharm trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $1.1B | XXX | XXX | XXX | XXX | $1.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, ST Pharm has market cap of $1.1B and EV of $1.1B.
ST Pharm's trades at 5.4x LTM EV/Revenue multiple, and 25.7x LTM EBITDA.
Analysts estimate ST Pharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for ST Pharm and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 5.7x | XXX | XXX | XXX |
| EV/EBITDA | 20.5x | XXX | XXX | XXX |
| P/E | 45.0x | XXX | XXX | XXX |
| P/E/Growth | 1.7x | XXX | XXX | XXX |
| EV/FCF | 59.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpST Pharm's NTM/LTM revenue growth is 19%
ST Pharm's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, ST Pharm's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate ST Pharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for ST Pharm and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -4% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 45% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 47% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 25% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ST Pharm acquired XXX companies to date.
Last acquisition by ST Pharm was XXXXXXXX, XXXXX XXXXX XXXXXX . ST Pharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was ST Pharm founded? | ST Pharm was founded in 2008. |
| Where is ST Pharm headquartered? | ST Pharm is headquartered in South Korea. |
| Who is the CEO of ST Pharm? | ST Pharm's CEO is Mr. Kyung-jin Kim. |
| Is ST Pharm publicy listed? | Yes, ST Pharm is a public company listed on KRX. |
| What is the stock symbol of ST Pharm? | ST Pharm trades under 237690 ticker. |
| When did ST Pharm go public? | ST Pharm went public in 2016. |
| Who are competitors of ST Pharm? | Similar companies to ST Pharm include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of ST Pharm? | ST Pharm's current market cap is $1.1B |
| What is the current revenue of ST Pharm? | ST Pharm's last 12-month revenue is $197M. |
| What is the current EBITDA of ST Pharm? | ST Pharm's last 12-month EBITDA is $41.4M. |
| What is the current EV/Revenue multiple of ST Pharm? | Current revenue multiple of ST Pharm is 5.4x. |
| What is the current EV/EBITDA multiple of ST Pharm? | Current EBITDA multiple of ST Pharm is 25.7x. |
| What is the current revenue growth of ST Pharm? | ST Pharm revenue growth between 2023 and 2024 was -4%. |
| Is ST Pharm profitable? | Yes, ST Pharm is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
